ABBOTT INDIA LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: Private

Established: 1888-01-01

Employees: 73K

Market Cap: $7.5B

Website: http://www.abbott.com

Clinical Trials

A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects

Phase 2

Completed

Conditions: Hypocalcemia

First Posted Date: 2003-01-28

Last Posted Date: 2006-08-02

Lead Sponsor: Abbott

Target Recruit Count: 45

Registration Number: NCT00053378

Locations: 🇺🇸
St. Luke's Hospital, Bethlehem, Pennsylvania, United States
🇺🇸
Merced Heart Association, Merced, California, United States
🇺🇸
Central Baptist Hospital Clinical Research Center, Lexington, Kentucky, United States

and more 6 locations

Atrasentan in Treating Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2011-02-21

Lead Sponsor: Abbott

Registration Number: NCT00046943

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States

Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis

Phase 3

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2002-11-14

Last Posted Date: 2006-08-15

Lead Sponsor: Abbott

Target Recruit Count: 3000

Registration Number: NCT00049751

Locations: 🇺🇸
Freeman Health Systems, Joplin, Missouri, United States
🇺🇸
Rheumatology Clinic, Los Angeles, California, United States
🇺🇸
Pain Therapy Center, Schaumburg, Illinois, United States

and more 50 locations

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)

Phase 3

Completed

Conditions: Arthritis, Juvenile Idiopathic

Interventions: Biological: Double-Blind Adalimumab/Placebo + MTX
Biological: Double-Blind Adalimumab/Placebo
Drug: OLE BSA Adalimumab +/- MTX
Drug: OLE FD Adalimumab +/- MTX

First Posted Date: 2002-11-05

Last Posted Date: 2011-08-22

Lead Sponsor: Abbott

Target Recruit Count: 171

Registration Number: NCT00048542

Locations: 🇺🇸
Site Reference ID/Investigator# 644, Kansas City, Kansas, United States
🇺🇸
Site Reference ID/Investigator# 642, Stanford, California, United States
🇺🇸
Site Reference ID/Investigator# 406, Norfolk, Virginia, United States

and more 28 locations

Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure.

Phase 3

Completed

Conditions: Heart Failure, Congestive

First Posted Date: 2002-11-04

Last Posted Date: 2006-12-15

Lead Sponsor: Abbott

Target Recruit Count: 600

Registration Number: NCT00048425

Locations: 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

and more 163 locations

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)

Phase 3

Completed

Conditions: Renal Insufficiency, Chronic

First Posted Date: 2002-11-04

Last Posted Date: 2006-08-02

Lead Sponsor: Abbott

Target Recruit Count: 68

Registration Number: NCT00048516

Locations: 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
🇵🇱
Wojewodzki Szpital Specjalistyczny AM w Bialymstoku, Bialymstoku, Poland
🇺🇸
VA Greater Los Angeles Healthcare System, West Los Angeles, Los Angeles, California, United States

and more 15 locations

Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Phase 3

Completed

Conditions: Renal Insufficiency, Chronic

First Posted Date: 2002-11-04

Last Posted Date: 2006-08-02

Lead Sponsor: Abbott

Target Recruit Count: 68

Registration Number: NCT00048451

Locations: 🇺🇸
Medisphere Medical Research Center, Evansville, Indiana, United States
🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Biolab Research, LLC, Rockville, Maryland, United States

and more 15 locations

Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)

Phase 3

Completed

Conditions: Renal Insufficiency, Chronic

First Posted Date: 2002-11-04

Last Posted Date: 2006-08-15

Lead Sponsor: Abbott

Target Recruit Count: 68

Registration Number: NCT00048438

Locations: 🇺🇸
Nephrology Association of South Miami, Miami, Florida, United States
🇺🇸
Dallas Nephrology Associates, Dallas, Texas, United States
🇺🇸
Arms, Dodge, Robinson, Wilber and Crouch, Kansas City, Missouri, United States

and more 15 locations

Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects

Phase 3

Completed

Conditions: HIV Infections

First Posted Date: 2002-08-19

Last Posted Date: 2006-07-27

Lead Sponsor: Abbott

Target Recruit Count: 200

Registration Number: NCT00043966

Locations: 🇺🇸
Phoenix Body Positive, Phoenix,, Arizona, United States
🇺🇸
Akron Infectious Disease, Inc., Akron, Ohio, United States
🇺🇸
Donna E. Sweet, MD, Wichita,, Kansas, United States

and more 49 locations

Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2002-08-19

Last Posted Date: 2007-09-27

Lead Sponsor: Abbott

Target Recruit Count: 30

Registration Number: NCT00043953

Locations: 🇺🇸
Stephen Becker, MD, San Francisco,, California, United States
🇺🇸
Community Research Initiative of New England, Springfield, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 7 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy